Jump to Main Content

ASH Annual Meeting and Exposition

Annual Meeting Sessions on Diversity, Equity, and Inclusion

As a global hematology community, ASH understands the importance of having individuals with diverse perspectives and experiences in all areas of the field. As a subspecialty in medicine, we are all striving to improve the outcomes for individuals with hematologic diseases. One tool in our toolkit to improve outcomes is a deeper understanding of causes of disparities in outcomes for our patients. We invite you to learn more and participate in the following sessions at the 64th ASH Annual Meeting to learn more about the science of how differences in identity impact outcomes and how to mitigate those differences and achieve equitable outcomes for all individuals with hematologic diseases and disorders.


Blood Journals Studio

Distinguished Abstract Achievement Award Ceremony (for in-person participants)


Saturday, December 9, 2023, 2:00 p.m. - 3:30 p.m.
San Diego Convention Center , Halls G-H - Blood Journals Studio

This event honors the recipients of the Distinguished Abstract Achievement Awards across various categories. This event is open to all meeting participants. The awards being presented, and winners being honored include:

ASH Outstanding Abstract Achievement Award

Rajagopalan Subramaniam    
Anagha Sheth, BSc
Moritz Fürstenau, MD
Zhaofeng Zheng    
Mirca Saurty-Seerunghen, PhD

ASH-BSH Abstract Achievement Award

I-Jun Lau, DPhil, BMBCh
Maryam Subhan    
Nikolaos Sousos, MD, MSc, PGCert, DPhil

ASH-HSANZ Abstract Achievement Award

James Kuzich, MBBS, FRACP, FRCPA

ASH-JSH Abstract Achievement Award

Kenki Saito
Satoshi Kaito, MD, PhD
Rurika Okuda, MSc,BS

ASH-SIE Abstract Achievement Award

Enrico Attardi, MD
Luca Lanino, MD

ASH-IPIG Abstract Achievement Award for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Carlos Bravo-Perez, MD
Hiroki Mizumaki, MD, PhD

ASH-Frank Toohey Abstract Achievement Award for Myelodysplastic Syndromes

Cristina Astrid Tentori, MD

Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis

Lucas Van Gorder

Joanne Levy, MD Memorial Award for Outstanding Achievement

Matthew Frank, MD, PhD

ASH Minority Graduate Student Abstract Achievement Award

Charles Ayemoba
Corbin Azucenas
Ginette Balbin-Cuesta
Claudia Cabrera
Daisy Diaz Rohena
Ariel Leyte-Vidal
Francisco Marchi
Richard Marrero
Jonny Mendoza-Castrejon
Fathima Mohamed
Justin Thomas
Eudorah Vital

back to top

Education Program

Hematologists and the Care of Pregnant Women


Sunday, December 10, 2023, 4:30 p.m. - 5:45 p.m.
San Diego Convention Center , Room 25

This session, dedicated to the memory and legacy of Dr Claire McLintock, will provide examples of the clinical roles played by hematologists in caring for patients during pregnancy. Dr Adam Lewkowitz will provide an overview of the diagnosis and treatment of iron deficiency in pregnancy including appropriate management to improve outcome for both mother and baby and a discussion of treatment options in pregnancy. Dr Andra James will provide an evidence-based overview of the management of patients with bleeding disorders in pregnancy, highlighting the importance of multidisciplinary care. Dr Fionnuala Ní Áinle will review the prevention, diagnosis and management of venous thromboembolism in pregnancy and will discuss ongoing and recently published landmark clinical trials.

Chair:

Fionnuala Ni Ainle, MD, PhD
Mater Misericordiae University Hospital, University College Dublin
Dublin 7,  Ireland

Speakers:

Andra H James, MD
Duke
Durham,  NC
Management of Pregnant Women Who Have Bleeding Disorders

Adam K Lewkowitz, MD
Brown University School of Medicine, Women and Infants Hospital In Rhode Island
Providence,  RI
Identifying and Treating Iron Deficiency Anemia in Pregnancy

Fionnuala Ni Ainle, MD, PhD
Mater Misericordiae University Hospital, University College Dublin
Dublin 7,  Ireland
Prevention, Diagnosis and Management of PE & DVT in Pregnant Women

back to top

Hot Topics in Blood Donation: Donor Risks and Social Justice


Sunday, December 10, 2023, 4:30 p.m. - 5:45 p.m.
San Diego Convention Center , Hall A

For years, men who have sex with men (MSM) were banned from donating blood to reduce the risk of transfusion-transmitted HIV. Several countries, including the US, have recently instituted individualized risk assessment policies to try to balance fairness to potential donors with the safety of the blood supply. Meeting the demand for blood products also requires balancing patient needs with the safety of volunteer blood donors. This session will review evolving policies for selecting blood donors as well as two potential hematologic consequences of frequent donation, clonal hematopoiesis and T-cell lymphopenia.

Chair:

Richard M Kaufman, MD
Brigham and Women's Hospital, Harvard Medical School
Boston,  MA

Speakers:

Mindy Goldman, MD
Canadian Blood Services
Ottawa,  ON, Canada
MSM and Blood Donation: Shifting to Individualized Risk Assessment

Darja Karpova, MD
Washington University in St. Louis
Saint Louis,  MO
Clonal hematopoiesis in Frequent Whole Blood Donors

Richard M Kaufman, MD
Brigham and Women's Hospital, Harvard Medical School
Boston,  MA
T-cell Lymphopenia in Frequent Platelet Donors

back to top

How Can We Manage High-Risk Hematologic Malignancies in the Community?


Monday, December 11, 2023, 4:30 p.m. - 5:45 p.m.
Manchester Grand Hyatt San Diego , Grand Hall B

The complexity of treating hematologic malignancies continues to grow rapidly with novel agents, BiTe therapy, CAR-T, and transplantation, which offer potentially a new horizon for patients struggling with these diseases. As these therapies are becoming the stand of care, the question of access remains a large factor in improving patient outcomes in the community where most of the cancer care is delivered. This educational session will explore the diagnostic, supportive, and treatment challenges that often present in the local setting with acute leukemia, high grade lymphomas, and multiple myeloma. We offer a case-based discussion for optimal management, as well as explore the role of clinical trials locally in terms of increasing access, diversity, options, and outcomes in the community.

Chair:

Dipti Patel-Donnelly, MD
Virginia Cancer Specialists
Fairfax,  VA

Speakers:

Dipti Patel-Donnelly, MD
Virginia Cancer Specialists
Fairfax,  VA
Acute Leukemias and Complicated Lymphomas: Pearls to Optimize Management When Patients Stay Local

Jesus G. Berdeja, MD
Sarah Cannon Research Institute
Nashville,  TN
Multiple Myeloma: A Paradigm for Blending Community and Academic Care

Ruemu E. Birhiray, MD
Hem.-Onc. of Indiana, PC
Indianapolis,  IN
Clinical Research in the Community

back to top

Improving Outcomes for Individuals With Sickle Cell Disease: Are We Moving the Needle?


Monday, December 11, 2023, 4:30 p.m. - 5:45 p.m.
San Diego Convention Center , Room 29

Sickle cell disease (SCD) can lead to debilitating morbidity and premature mortality. Over the past decade, 3 new drugs have been FDA-approved for treating children and adults with SCD, and many others are actively being studied. Similarly, novel curative approaches are increasingly becoming available. Unfortunately, a paucity of data exists regarding whether outcomes are improving in individuals with SCD. 

Dr. Ken Ataga will discuss disease-modifying therapies that are currently FDA-approved and some of the most promising drugs that are underway.

Dr. Adetola Kassim will describe the most recent outcomes of haploidentical hematopoietic cell transplantation compared to more traditional approaches. He will also compare the pros and cons of various haploidentical platforms that are currently available.

Dr. John Tisdale will discuss the encouraging results of gene therapy and gene editing trials for patients with SCD and the remaining challenges.

Chair:

Courtney D. Fitzhugh, MD
NIH (Hematology)
Bethesda,  MD

Speakers:

Kenneth I. Ataga, MD
University of Tennessee Health Sciences Center
Memphis,  TN
Using Disease Modifying Therapies in Sickle Cell Disease

Adetola A. Kassim, MBBS,MS
Vanderbilt University
Nashville,  TN
The Range of Haploidentical Transplant Protocols in Sickle Cell Disease: All Haplos Are Not Created Equally

John F. Tisdale, MD
NIH
Bethesda,  MD
Gene Therapy for Sickle Cell Disease

back to top

Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL?


Monday, December 11, 2023, 2:45 p.m. - 4:00 p.m.
Manchester Grand Hyatt San Diego , Grand Hall B

Adolescents and young adult patients (AYA) represent a unique population of patients with acute lymphoblastic leukemia (ALL). AYA patients do not fit squarely into either pediatric or adult cohorts. Unfortunately, AYA patients have been shown to have differential outcomes than older and younger patients with ALL. This educational session will explore describe approaches to therapy, differences between AYA and pediatric patients with ALL, and options for improving outcomes for this patient population. Dr. John Molina will review the current outcomes from AYA patients with B-ALL treated with commonly used pediatric or “pediatric-inspired” regimens in the upfront setting. He will discuss the ongoing clinical trials incorporating immunotherapies into the existing chemotherapy backbones and any available preliminary results, as well as the shift to next generation sequencing (NGS) for measurable residual disease (MRD) assessment. Finally, with the introduction of novel therapies into the upfront setting and improved disease response evaluation, he will review the changing role of hematopoietic stem cell transplant (HSCT) as consolidative therapy for AYA patients achieving a first, complete remission. Dr. Tamara P. Miller will then review the differences between AYA patients and pediatric patients in terms of survival, risks, and barriers to enrollment. She will describe contrasts in genetic risk factors and development of toxicities. She will discuss the range of treatment, trial enrollment and psychosocial challenges that are differ between AYA and pediatric patients. Finally, Dr. Emily Curran will review novel strategies to improve outcomes for AYAs. She will discuss ongoing work to overcome the adverse disease biology that is more common among AYAs with ALL. She will describe ways to leverage technology to improve adherence and try to address psychosocial challenges. Finally, she will review differences in healthcare delivery for AYAs with ALL and need for increased enrollment in clinical trials.

Chair:

Tamara P. Miller, MD
Children's Healthcare of Atlanta
Atlanta,  GA

Speakers:

John C Molina, MD,MEd
Taussig Cancer Institute, Cleveland Clinic Foundation
Cleveland,  OH
Leveraging Health Care Technology to Improve Health Outcomes and Reduce Outcome Disparities in AYA Leukemia

Tamara P. Miller, MD
Children's Healthcare of Atlanta
Atlanta,  GA
Adolescent and Young Adults (AYA) Versus Pediatric Patients: Survival, Risks and Barriers to Enrollment

Emily K Curran, MD
University of Cincinnati
Cincinnati,  OH
Acute Lymphoblastic Leukemia in Young Adults: Which Treatment?

back to top

The Iron Revolution!


Sunday, December 10, 2023, 9:30 a.m. - 10: 45 a.m.
San Diego Convention Center , Room 28 A-D

A revolution is defined as a great and sudden change. Our speakers will discuss how in iron deficiency we need to change how we use laboratory tests to diagnose iron deficiency to insure we are correctly diagnosing ALL with iron deficiency and not just the select few with severe iron depletion.  For therapy we need to recognized oral iron either fails or is not appropriate for many patients and that intravenous iron is safe and effective

Dr. Deloughery will discuss what ferritin is and why it is used as a measure of body iron stores.  Then he will demonstrate the high incidence of iron deficiency in women - up to 50% of healthy women with absent iron stores on bone marrow exam.  Finally, he will advocate that ferritin cuts off need to be much higher to properly diagnose iron deficiency in all affected women and the implications of such a change. 

In this section on The Iron Revolution, Dr Auerbach will be highlighting the administration of the four available iron products permitting complete replacement dosing in a single setting. He will discuss methods of administration, safety, and indications. Most importantly he will dispel notions of danger created by antiquated folklore and show a video of a minor infusion reaction, how to manage it, and how the inappropriate intervention for the minor reaction can lead to a hemodynamically significant serious adverse event ostensibly and inappropriately ascribed to the IV iron. 

Dr Powers will discuss that iron deficiency anemia occurs most commonly in young children due to low iron diet and adolescent girls due to menstrual blood loss. However, children with gastrointestinal conditions such as intestinal failure, inflammatory bowel disease, celiac disease, and/or other chronic conditions including chronic kidney disease and heart failure, also commonly have iron deficiency. In children who have an incomplete response to oral iron, intravenous iron therapy is increasingly being utilized with benefits such as rapid repletion of iron stores, in addition to resolution of anemia, less gastrointestinal side effects, and relief for patients and families struggling with long-term iron supplementation. Four intravenous iron formulations have approved indications in pediatrics and many are increasingly utilized off-label in children as well. Here we discuss the indications and appropriate timing of intravenous iron therapy in children with a wide range of underlying etiologies. 

Chair:

Thomas G Deloughery, MD
Oregon Health and Science Univ.
Portland,  OR

Speakers:

Thomas G Deloughery, MD
Oregon Health and Science Univ.
Portland,  OR
Sex, Lies, and Iron Deficiency: A Call to Change Ferritin Reference Ranges

Michael Auerbach, MD
Auerbach Hem-Onc Associates, Inc.
Baltimore,  MD
IV Iron Formulations and Use in Adults

Jacquelyn Powers, MD
Baylor College of Medicine/ Texas Children's Hospital
Houston,  TX
Intravenous Iron Therapy in Pediatrics: Who Should Get It and When Is the Right Time?

back to top

Transfusion Support in Sickle Cell Disease


Saturday, December 9, 2023, 2:00 p.m. - 3:15 p.m.
San Diego Convention Center , Room 28 A-D

In patients with sickle cell disease (SCD), transfusion, by modifying the hemoglobin (Hb)A/HbS red blood cell (RBC) ratio, remains a major treatment to prevent or treat acute vaso-occlusive or chronic complications. Dr. Anoosha Habibi will discuss the indications for transfusion during pregnancy. Pregnancy is a high-risk situation for both mother and child. Recent studies and meta-analyses tend to favor transfusion during pregnancy, but no randomized studies have been conducted to date. The frequency of transfusion complications in pregnant women, such as post-transfusion hyperhemolysis, makes decision-making difficult. As recommended by the ASH guidelines, the decision should be made case-by-case, based on each patient's transfusion history and complications associated with SCD. Dr. Shannon Kelly will review the different transfusion methods that are available when transfusion is indicated : simple RBC transfusion or RBC exchange which can be automated or manual. The role of these different methods depends not only on local resources, but also on the transfusion indication and a number of patient-dependent parameters. Risks and benefits will be discussed. Dr. France Pirenne will define the patients at risk for transfusion: they are those who previously developed RBC antibodies and/or post-transfusion hyperhemolysis. In these situations, prevention of additional reactions with specific transfusion protocols is necessary, immunosupressive therapy is frequently given, and close transfusion monitoring is implemented. In patients with severe disease, hematopoietic stem cell transplantation may be indicated. However, transfusion is also required in this context, and its management is complex as transfusion risks must be taken into account.

Chair:

France Pirenne, MD, PhD
Université Paris-Est Créteil , Henri Mondor Hospital
Créteil,  France

Speakers:

Anoosha Habibi, MD
Henri-Mondor University Hospital- UPEC, AP-HP
Creteil Cedex,  FRA
Managing Pregnancy in Patients with Sickle Cell Disease from a Transfusion Perspective

Shannon Kelly
UCSF Benioff Children's Hospital Oakland
Oakland,  CA
Logistics, Risks and Benefits of Automated Red Blood Cell Exchange for Patients with Sickle Cell Disease

France Pirenne, MD, PhD
Université Paris-Est Créteil , Henri Mondor Hospital
Créteil,  France
Alloimmunization and Hyperhemolysis in Sickle Cell Disease

back to top

Health Equity Studio

Community Partnerships: An Essential Component to Advance Health Equity


Saturday, December 9, 2023
11: 00 a.m. - 11: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
11: 00 a.m. - 11: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
11: 00 a.m. - 11: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
11: 00 a.m. - 11: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
4:00 p.m. - 4:30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
4:00 p.m. - 4:30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
4:00 p.m. - 4:30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
4:00 p.m. - 4:30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio

Community partnerships can help to identify and alleviate some of the disparities caused by social determinants of health. Dr. Titilope Fasipe shares her story with sickle cell disease as a patient and physician discussing best practices to partner with community groups.

back to top

How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective


Saturday, December 9, 2023
1:30 p.m. - 2:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
1:30 p.m. - 2:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
1:30 p.m. - 2:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
1:30 p.m. - 2:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
8:15 a.m. - 8:45 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
8:15 a.m. - 8:45 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
8:15 a.m. - 8:45 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
8:15 a.m. - 8:45 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio

Dr. Susanna Curtis explains the importance of language when advocating for your LGBTQIA+ patients, trainees, and colleagues. Using real life experiences, they share efforts on how to move the needle at your institution. This session highlights how to advocate for patients in clinical settings.

back to top

Legally Intentional: Overcoming Barriers to Inclusion in the Hematology Workforce


Sunday, December 10, 2023
11: 00 a.m. - 11: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
11: 00 a.m. - 11: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
11: 00 a.m. - 11: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
11: 00 a.m. - 11: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
1:00 p.m. - 1:30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
1:00 p.m. - 1:30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
1:00 p.m. - 1:30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
1:00 p.m. - 1:30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio

Dr. Curtis Henry addresses equity in healthcare in a post-affirmative action environment. Dr. Henry uses real life examples to illustrate how you can help empower underrepresented trainees and faculty in hematology. This session provides you with key strategies to create change in your institution.

back to top

Outcome Disparities in Hematologic Diseases: The Importance of Social Determinants of Health


Saturday, December 9, 2023
9:00 a.m. - 9:30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
9:00 a.m. - 9:30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
9:00 a.m. - 9:30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
9:00 a.m. - 9:30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
1:30 p.m. - 2:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
1:30 p.m. - 2:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
1:30 p.m. - 2:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
1:30 p.m. - 2:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio

Racial and ethnic disparities in blood diseases raise questions about the influence of social determinants of health. Dr. Justine Kahn talks about how addressing disparities requires incorporating assessments of social determinants into our clinical practice, research programs, and into medical education.

back to top

Systemic Racism in Hematology


Sunday, December 10, 2023
9:00 a.m. - 9:30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
9:00 a.m. - 9:30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
9:00 a.m. - 9:30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Sunday, December 10, 2023
9:00 a.m. - 9:30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
12: 00 p.m. - 12: 30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
12: 00 p.m. - 12: 30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
12: 00 p.m. - 12: 30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
12: 00 p.m. - 12: 30 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio

Dr. Maureen Achebe uses a multiple myeloma case to demonstrate how systemic racism negatively impacts hematology patient outcomes. Practical strategies are discussed to reduce implicit bias and the effect racism has on patients.

back to top

Using Research to Advance Equity in the LGBTQIA+ Space


Saturday, December 9, 2023
3:30 p.m. - 4:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
3:30 p.m. - 4:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
3:30 p.m. - 4:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Saturday, December 9, 2023
3:30 p.m. - 4:00 p.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
10: 00 a.m. - 10: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
10: 00 a.m. - 10: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
10: 00 a.m. - 10: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio
Monday, December 11, 2023
10: 00 a.m. - 10: 30 a.m.

San Diego Convention Center , Sails Pavilion - ASH Health Equity Studio

Dr. Warren Fingrut illustrates the history of mistrust for LGBTQIA+ peoples with the healthcare system. He provides an overview of existing research while highlighting the gaps that remain to address barriers to inclusion impacting LGBTQIA+ patients and donors. Dr. Fingrut emphasizes the importance of identifying this population in practice to advance equity for these patients through research.

back to top

Special-Interest Sessions

2023 ASH Guideline Implementation Champions


Sunday, December 10, 2023, 9:30 a.m. - 11: 00 a.m.
San Diego Convention Center , Room 7

This session, led by Drs. Rachel Rosovsky and Amy Billett, recognizes practitioners who have been working to implement recommendations for evidence-based guidelines at the point of care in their clinical settings. Each year, a few individuals are selected from a pool of applicants to present their strategies for successful implementation.   

CoChair:

Speakers:

Christina Marie Ruiz, MD
University of California San Diego School of Medicine
San Diego,  CA
Improving the Outpatient Pain Management Plan for Patients with Sickle Cell Disease with Innovative Pain Action Plan

Gabriella Nguyen, MD
University of Texas Southwestern
Dallas,  TX
Steering Change with COMPASS: Clinical Pathway to Optimize the Management of Pediatric Acute Stroke in Sickle Cell Disease

back to top

ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)


Monday, December 11, 2023, 6:15 p.m. - 8:00 p.m.
San Diego Convention Center , Room 28 A-D & Plaza Terrace

Meeting attendees with an interest in sickle cell are invited to this reception, which will celebrate progress in sickle cell and provide an opportunity to network.  Through the Sickle Cell Disease (SCD) Initiative, ASH and the ASH Research Collaborative (ASH RC) have made significant progress in 2023 to support advances in research, improving provider training and education, advocating for policies to expand access to care, and enhancing data collection.  The program will feature Dr. Mohandas Narla, ASH President-Elect, and Dr. Alexis Thompson, Chair of the ASH Research Collaborative SCD Data Hub, and SCD Learning Community Subcommittees, presenting a brief snapshot of the advances the ASH and the ASH RC have made to drive change in sickle cell disease over the past year. The remaining part of the program will provide ample time for networking.

back to top

Blood and Beyond


Sunday, December 10, 2023, 4:30 p.m. - 6:00 p.m.
San Diego Convention Center , Room 24

The editors of the Blood journal will highlight the intersection of hematology and the humanities in a session entitled Blood & Beyond. For this year, in complement to the celebration of the 20th anniversary of ASH’s Minority Recruitment Initiative, the session: Un-walling Health and Well-Being: Shared Destinies at the San Diego-Tijuana Border will be presented by Teddy Cruz and Fonna Forman and will consider the intersection of diversity, equity and inclusion, migration, and social policy. Fonna Forman and Teddy Cruz will discuss the eco-social impacts of increasing migration across the US-Mexico border region, and how the UCSD Center on Global Justice is responding to the challenge in Tijuana. This includes the construction of emergency housing, and the coordination of education, vocational training, employment, cultural activity, and health services. 

Teddy Cruz and Fonna Forman are principals in Estudio Teddy Cruz + Fonna Forman, a research-based political and architectural practice in San Diego, CA, transgressing conventional boundaries between theory and practice and merging the fields of architecture and urbanism, political theory, and urban policy. The practice investigates issues of informal urbanization, civic infrastructure, and public culture, with a special emphasis on Latin American cities. Cruz and Forman lead a variety of urban research agendas and civic/public interventions in the San Diego-Tijuana border region, and beyond. From 2012-13, they served as special advisors on civic and urban initiatives for the City of San Diego and led the development of its Civic Innovation Lab. Together, they lead the UCSD Community Stations, a platform for community-engaged research and teaching on poverty and social equity in the border region.

CoChair:

Speakers:

Teddy Cruz, MDes
Estudio Teddy Cruz + Fonna Forman
San Diego,  CA
Un-walling Health and Well-Being: Shared destinies at the San Diego-Tijuana Border

Fonna Forman, PhD
Estudio Teddy Cruz + Fonna Forman
San Diego,  CA
Un-walling Health and Well-Being: Shared destinies at the San Diego-Tijuana Border

back to top

Health Equity Rounds Lunch (for in-person participants)


Sunday, December 10, 2023, 11: 15 a.m. - 12: 15 p.m.
Hilton San Diego Bayfront , Sapphire Ballroom CD

Health Equity Rounds are interactive, case-based discussions with an interdisciplinary panel to include hematologists, health equity/public health experts, patients, and patient advocates to discuss health equity issues within hematology. Lunch will be provided to in-person attendees.

Speakers:

Shakira J. Grant, MBBS,MSCR
ASH/AAAS Science and Policy Fellow
Washington,  DC
Health Workforce Diversity and Equity 1

Srinivas Devarakonda, MD
The Ohio State University
Columbus,  OH
Health Workforce Diversity and Equity 2

back to top

Maternal Health: Fertility Preservation in Hematology Care


Sunday, December 10, 2023, 9:30 a.m. - 11: 00 a.m.
San Diego Convention Center , Ballroom 20AB

Both patients with hematologic conditions and their hematologists face a complex set of challenges when considering options for fertility preservation. With new technologies available and a broader understanding of the need for fertility preservation, there are more opportunities available. This session will explore why there has been such a marked increase in demand for these options, what exactly the options and techniques available are and what both hematologists and their patients need to expect in success rates, complications and demands on their already busy schedules.

Chair:

Sarah O'Brien, MD,MSc
Nationwide Children's Hospital
Columbus,  OH

Speakers:

Erica Marsh, MD, MSCI, FACOG
University of Michigan
Ann Arbor,  MI
Fertility Health Equity and the Fertility Preservation Process

Alison W Loren, MD
University of Pennsylvania
Philadelphia,  PA
Fertility Care for Patients with Hematologic Conditions

Mindy Christianson, MD, MBA
Cleveland Clinic
Cleveland,  OH
Fertility Care for Physicians

back to top

Promoting Minorites in Hematology (PMH) MRI Anniversary Reception (for in-person participants)


Saturday, December 9, 2023, 8:00 p.m. - 9:00 p.m.
Marriott Marquis San Diego Marina , Marina Ballroom G

This year’s reception will commemorate the 20th Anniversary of the Minority Recruitment Initiative (MRI). Join us for the celebration following the oral presentations.

back to top

Promoting Minorities in Hematology (PMH) Oral Presentations: Room I (for in-person participants)


Saturday, December 9, 2023, 6:30 p.m. - 8:00 p.m.
Marriott Marquis San Diego Marina , Marina Ballroom D

ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity scholars in the field of hematology. The highlight of the session will be scientific presentations from the ASH Minority Medical Student Award, the ASH Minority Resident Hematology Award, the ASH Minority Hematology Graduate Award, and the ASH Minority Hematology Fellowship Award program participants.

A special reception celebrating the 20th anniversary of the Minority Recruitment Initiative (MRI) will follow presentations.

Speakers:

Ayo S Falade, MD,MBA
Mass General Brigham Salem Hospital
Salem,  MA
Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Bianca A Ulloa, PhD
Albert Einstein College of Medicine
Bronx,  NY
Pre-Clinical Developmental Hematopoiesis Cross-Species Comparative Analysis with KMT2A-Rearranged Infant Acute Lymphoblastic Leukemic Populations

Carla Barrientos Risso
Ponce Health Sciences University
Ponce,  Puerto Rico
Discovering Mechanisms of Noncovalent BTK Inhibitor Resistance in CLL

Dailia B. Francis, MD,PhD
Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta
Atlanta,  GA
The Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin Lymphomas

Danielle Sohai
Children's National Hospital
Washington,  DC
Expansion of KSHV-Specific T Cells for the Treatment of KSHV-Associated Malignancy

H. Moses Murdock, MD
Dana-Farber Cancer Institute
Boston,  MA
Molecular MRD in a Phase 1 Study of Maintenance Azacitidine/Venetoclax after RIC-Ven Allogeneic HSCT in High Risk Myeloid Malignancies

K. Ashley Lyttle
Meharry Medical College
Nashville,  TN
GPATCH8 As a Modulator of Mutant SF3B1

Marcus Alexander Florez, PhD
Baylor College of Medicine
Houston,  TX
Exploring the Underlying Mechanisms of BST2 in Hematopoietic Stem Cell Activation

Maria J. Fernandez Turizo, MD
Beth Israel Deaconess Medical Center, Harvard Medical School
Brookline,  MA
Novel Causal Inference Method Estimates Treatment Effects in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Omonike Oyelola
University of Connecticut School of Medicine
Farmington,  CT
Assessing Disease-Specific Alterations within the Bone Marrow Microenvironment in JAK2 Dependent Neoplasms

Tre Artis
Harvard University
Cambridge,  MA
Phenotypic and Molecular Consequences of Noncoding TET2 Perturbations in the Human Hematopoietic System

back to top

Promoting Minorities in Hematology (PMH) Oral Presentations: Room II (for in-person participants)


Saturday, December 9, 2023, 6:30 p.m. - 8:00 p.m.
Marriott Marquis San Diego Marina , Marina Ballroom E

ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity scholars in the field of hematology. The highlight of the session will be scientific presentations from the ASH Minority Medical Student Award, the ASH Minority Resident Hematology Award, the ASH Minority Hematology Graduate Award, and the ASH Minority Hematology Fellowship Award program participants.

A special reception celebrating the 20th anniversary of the Minority Recruitment Initiative (MRI) will follow presentations.

Speakers:

Abdi Abud
University of Missouri-Columbia School of Medicine
Saint Louis,  MO
Validation of a Natural Language Processing Tool for Identification of Acute Deep Venous Thrombosis

Andres Felipe Fajardo, MD
McMaster University
Hamilton,  ON, CAN
Intellectual Disability, Cancer, and Delayed Diagnosis: A Scoping Review

Elizabeth Rodriguez
The University of Texas Health Science Center at Houston
Houston,  TX
Investigating the Impact of Neighborhood Deprivation Level on Late-Term Outcomes in Adolescent and Young Adult Hodgkin Lymphoma Survivors

Elyse Lopez, MD
Baylor College of Medicine
Houston,  TX
Health Disparities in Acute Lymphoblastic Leukemia (ALL): A Focus on Adolescent and Young (AYA) Adult Patients and Temporal Trends over Ten Years

Jamie A.G. Hamilton, PhD
Emory University
Atlanta,  GA
Delineating How Obesity-Associated Chronic Inflammation Impacts B-Cell Acute Lymphoblastic Leukemia (B-ALL) Progression

Jorge David Avila, MD
St. Elizabeth's Medical Center
Boston,  MA
Marital Status, Frailty, and Survival in Older Adults with Blood Cancer

Josue Marquez-Garcia
The Warren Alpert Medical School of Brown University
Arlington,  MA
Assessing the Risk of Venous Thromboembolism and Bleeding Among Patients with Myeloproliferative Neoplasms Undergoing Total Knee and Hip Arthroplasty

Maria D. Leon-Camarena, MD
Dell Medical School at University of Texas
Austin,  TX
Association of Latino Ethnicity with Cytogenetic Subtype in Pediatric Acute Lymphoblastic Leukemia: A Report from the Reducing Ethnic Disparities in Acute

Oluwalonimi Adebowale, MD
Howard University College of Medicine
Washington,  DC
Biomarker, Cytokine and Gene Expression Signatures of Alloimmunization in Children with Sickle Cell Disease

Omolegho Momoh, MD
Montefiore New Rochelle Hospital
New Rochelle,  NY
Defining the Clinical Outcomes and Molecular Landscape of Acute Myeloid Leukemia (AML) in Nigeria

Tolulope Rosanwo, MD
Boston Children's Hospital
Boston,  MA
Approaches to Evaluate HbF Determinants in Genome Editing for Sickle Cell Disease

back to top

Promoting Minorities in Hematology (PMH) Oral Presentations: Room III (for in-person participants)


Saturday, December 9, 2023, 6:30 p.m. - 8:00 p.m.
Marriott Marquis San Diego Marina , Marina Ballroom F

ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity scholars in the field of hematology. The highlight of the session will be scientific presentations from the ASH Minority Medical Student Award, the ASH Minority Resident Hematology Award, the ASH Minority Hematology Graduate Award, and the ASH Minority Hematology Fellowship Award program participants.

A special reception celebrating the 20th anniversary of the Minority Recruitment Initiative (MRI) will follow presentations.

Speakers:

Alexis Rae Williams, MD
Boston Children's Hospital
Boston,  MA
A Standardized Approach to Screening for Academic Challenges Among Patients with Sickle Cell Disease

Ashley Inez Thrower, BS
Duke University Medical Center
Durham,  NC
COVID-19 Vaccination Hesitancy in Adults with Sickle Cell Disease?

Bria Carrithers, MD
University of Alabama at Birmingham
Birmingham,  AL
Addressing Reproductive Education Among Young Adults with Sickle Cell Disease (SCD): Sickle Cell Reproductive Outreach and Education (ROE) Project

Emmanuella Oyogoa, DO
Oregon Health and Science University
Portland,  OR
Clinical Outcomes of Patients Referred for Asymptomatic Neutropenia: A Focus on Racial Disparities in Hematology

Gabriela Ramirez Cuebas, MD
University of Puerto Rico School of Medicine
San Juan,  PR
Assessing Primary Stroke Prevention Barriers and Facilitators in Children with Sickle Cell Anemia in Puerto Rico: A Mixed-Methods Study Design

Ijele Adimora, MD, MBA
The Johns Hopkins University School of Medicine
Baltimore,  MD
Neighborhood Disadvantage Increases Risk of Adverse Clinical Events in Children with Sickle Cell Disease

Mauricio Barreto, MD
Children’s National Hospital
Washington,  DC
Creatinine-Based Estimating Equations for GFR Outperform Cystatin C-Based Equations in Adults with Sickle Cell Disease

Nosakhare Paul Ilerhunmwuwa, MBBS,MSc
Brookdale University Hospital and Medical Center
Brooklyn,  NY
Factors Associated with Severity and Poor Outcomes in COVID-19 Infection in Patients with Sickle Cell Disease: A Single-Institution Experience

Sacha Choupa
Meharry Medical College School of Medicine
Nashville,  TN
Risk Factors for Thrombosis in Pregnant People with Sickle Cell Disease: A Multinational Study

Yaa Ofori-Marfoh, MSc,BS
Rush Medical College of Rush University
Durham,  NC
Experiences of Menopause in Women with Sickle Cell Disease

back to top

Special Scientific Session on Race and Science: Bench to Bedside to the Community


Sunday, December 10, 2023, 9:30 a.m. - 11: 00 a.m.
San Diego Convention Center , Hall A

Race is a prominent focus in academic health centers in the country, but what role do racial categories play in biomedical research or in the delivery of care to patients? Disparities in health care and disease outcomes exist, and there are racial groups who experience disproportionally worse outcomes and a shortened life expectancy. However, racial categories, as designed, represent social and biological factors that are not fully understood. How might we utilize race more appropriately – not to discriminate but to better understand the biology of disease while also delivering equitable care? This session is intended to serve as both the foundation and the beginning of a conversation on these critical issues.?Each speaker will present different perspectives on how and where to begin this discussion.  

Dr. Alisa Wolberg will discuss the role of the basic scientist and how the concepts of diversity, equity, and inclusion may be considered when designing investigations and experiments that will lead to data that is broadly generalizable and applicable.  

Dr. Saad Usmani will address the next step, regarding moving basic science to the bedside and discussing strategies that?assure clinical trials with novel therapies are inclusive and diverse.  

Ms. Shonta Chambers will provide the patient perspective and will highlight how best to engage with community and national organizations to strengthen the relationship between patients and the health care team to achieve the goal of equitable access to care and innovation. 

Dr. Nicole Gormley will present on the US Food and Drug Administration’s guidance on “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.” She will highlight the potential impact that regulatory agencies may have on clinical trial development.? 

CoChair:

Speakers:

Shonta Chambers, MSW
Patient Advocate Foundation
Hampton,  VA
Community and Patient Advocate Perspective

Saad Z Usmani, MD
Memorial Sloan Kettering Cancer Center
New York,  NY
Clinical Trial Perspective

Nicole Gormley, MD
US Food and Drug Administration
Silver Spring,  MD
Regulatory Perspective

Alisa S Wolberg, PhD
University of North Carolina at Chapel Hill
Chapel Hill,  NC
Basic Science Perspective

back to top

Special Session on Sickle Cell Disease Centers


Saturday, December 9, 2023, 9:30 a.m. - 11: 00 a.m.
San Diego Convention Center , Hall A

As care for people with sickle cell disease gets more complex and there are more treatment options available, it is imperative that all people with SCD receive care through a sickle cell center.

Over the last several years, ASH has developed a workshop and blueprint for the creation of Sickle Cell Disease Centers. Despite their necessity, it can still be difficult to ensure funding for these centers. This session will focus on alternative ways to supplement funding for sickle cell disease centers.

CoChair:

Speakers:

Sophie Lanzkron
Johns Hopkins Medical Institute
Baltimore,  MD
Maximizing Revenue from an Infusion Center

Julie Kanter, MD
University of Alabama At Birmingham
Birmingham,  AL
Partnering With Your Hospital On 340B

Alexis Kristine Leonard, MD
St. Jude Children's Research Hospital
Memphis,  TN
Getting Ready to Provide Genetic Therapies

back to top

Special Symposium on Quality - Identifying and Addressing Underuse in Hematologic Care


Saturday, December 9, 2023, 2:00 p.m. - 3:30 p.m.
San Diego Convention Center , Room 11

Underuse of appropriate tests, procedures, and therapies is a significant issue in hematology, resulting in negative outcomes for both individuals and populations.  This special symposium will identify three key areas of underuse in hematology and provide recommendations for addressing them:

  • Retrieval of inferior vena cava (IVC) filters
  • Use of hydroxyurea in patients with sickle cell disease
  • Patient education prior to anticoagulation

This session will encourage all stakeholders to incorporate strategies for identifying and addressing underuse into their quality improvement efforts.

CoChair:

Speakers:

Geoffrey D. Barnes, MD, MSc
University of Michigan
Ann Arbor,  MI
IVC Filter Retrieval

Alexandra Power-Hays, MD
University of Cincinnati College of Medicine
Cincinnati,  OH
Hydroxyurea in Sickle Cell Disease

Allison E. Burnett, PharmD
University of New Mexico Health Sciences Center
Albquerque,  NM
Patient Education Prior to Anticoagulation

back to top

Wake Up To DEI Networking Breakfast (for in-person participants)


Monday, December 11, 2023, 7:00 a.m. - 8:30 a.m.
Marriott Marquis San Diego Marina , Marina Ballroom

This is a community-building and networking event for members that fall within the diversity, equity, and inclusion (DEI) umbrella to gather and get to know each other across the varying and intersectional communities. The event will include remarks from a member of the ASH Committee on Diversity, Equity, and Inclusion. 

The event is hosted by the ASH DEI Programs Subcommittee and aims to create space for ASH DEI communities and allies and, where possible, identify opportunities to learn more about the experiences and needs of these communities to allow ASH to have a greater impact in its DEI efforts. 

back to top

Women In Hematology Networking Event (for in-person participants)


Monday, December 11, 2023, 7:30 p.m. - 9:30 p.m.
Manchester Grand Hyatt San Diego , Coronado Ballroom & Terrace

This popular annual reception will provide a space where all can gather in an informal environment and connect with peers and potential mentors. The event will include a panel discussion focused on leadership through a gender and career development lens as well as ample networking opportunities.

Spotlight Sessions

Tackling Greater Burden of Multiple Myeloma in African American Patients.


Sunday, December 10, 2023, 4:30 p.m. - 5:45 p.m.
San Diego Convention Center , Room 6B

Multiple myeloma (MM) is twice as common in African American (AA) patients with a higher mortality rate as compared to Whites. Increased use of stem cell transplantation and availability of highly effective, novel therapies have resulted in significantly improved survival in White patients with MM, while it is still lagging in AA. However, when provided with equal access to therapies, AA with MM have similar or even better outcomes compared to Whites. This underscores the role of race as a social construct and not merely a biologic entity in MM, and the need to better understand and address these health care disparities to achieve equal outcomes. This session will highlight recent research that enhances our understanding of the multiple mechanisms by which racial disparities influence the differential outcomes in AA with MM, and potential measures to bridge this health inequity.

Dr. Yvonne Efebera will discuss the role of race in healthcare disparities in AA with MM. She will provide an overview of the interplay of various factors including biological, socioeconomic, environmental, and systemic determinants impacting access to healthcare and outcomes in patients with MM. Dr. Efebera will discuss ongoing scientific research and emerging concepts that support equitable care as a means to tackle the greater burden of MM in AA.

Dr. Srinivas Devarakonda will address the significance of the need for representation of AA in scientific research in MM to reduce the outcome disparities. Enrollment of AA into genomic studies and clinical trials is vital to study the unique tumor and host biology, and increase the applicability of the research behind approved MM therapies. Dr. Devarakonda will discuss the barriers to accrual and various methods to improve the clinical trial enrollment of AA with MM including redesigning the trials to increase their eligibility.

CoChair:

Speakers:

Yvonne Adeduni Efebera, MD, MPH
OhioHealth
Columbus,  OH
Interplay of Healthcare Access and Outcomes in Multiple Myeloma

Srinivas Devarakonda, MD
The Ohio State University
Columbus,  OH
Redesigning Clinical Trials in Multiple Myeloma - Need of the Hour.

back to top

What is a “Normal” Neutrophil Count? The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution


Monday, December 11, 2023, 2:45 p.m. - 4:00 p.m.
San Diego Convention Center , Hall A

It is well-established that the absolute neutrophil count (ANC) in many individuals of African and Middle Eastern ancestry is lower than that in White individuals. This lower ANC is associated with homozygosity for a single nucleotide polymorphism (rs2814778) in the promoter region of the Duffy antigen receptor of chemokines (DARC) gene (also called ACKR1, atypical chemokine receptor 1) which confers the Duffy null phenotype [Fy(a-b-)]. This was historically called ‘benign ethnic neutropenia’, but the preferred term is Duffy-null associated neutrophil count, DANC. Several studies indicate that the Duffy-null genotype causes a change in the morphology of neutrophils, facilitating their migration into tissues, thus reducing the number of circulating neutrophils and causing an ‘apparent neutropenia’. Indeed, individuals who have DANC have circulating neutrophil counts that are approximately 2000/uL lower than Duffy non-null individuals, normal bone marrow cellularity and maturation, and a robust response to infections. The Duffy-null genotype is not associated with an increased risk of infection, yet individuals with DANC may experience iatrogenic adverse health outcomes due to their Duffy-null status. This session will be based on cases derived from clinical practice that will highlight the issues that arise from misinterpretation of the ANC in an individual with DANC. With knowledge of this genetic association, normal neutrophil count limits should not be defined by race or ethnicity, but by genetics. Dr. Lauren Merz will discuss the distribution and prevalence of the Duffy null phenotype as well as the selective pressures that likely led to the evolution of this variant. She will describe the physiological impact of this variant on neutrophil behavior and localization. Furthermore, Dr. Merz will review the assessment, development, and implementation of a Duffy null specific ANC reference range. Dr. Mark Sloan will provide an overview of the expected neutrophil count in persons with the Fy(a-b-) phenotype and suggest potential changes to avoid pathologizing healthy individuals. Dr. Sloan will also discuss the clinical implications of the Duffy null phenotype, including its impact on clinical research.

Chair:

Maureen Okam Achebe, MD,MPH
Brigham and Women's Hospital
Boston,  MA

Speakers:

Lauren E. Merz, MD,MSc
Dana-Farber Cancer Institute
Boston,  MA
Duffy-null Associated Neutrophil Counts--What is Normal

John Mark Sloan, MD
Boston University School of Medicine
Boston,  MA
Clinical Implications of the Duffy Antigen

back to top

Trainee Activities and Services

Blood Buddies: Diversity, Equity, and Inclusion


Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 J
Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 J
Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 J
Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 J
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 J
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 J
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 J
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 J

back to top

Blood Buddies: Medical Education


Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 G
Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 G
Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 G
Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 G
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 G
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 G
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 G
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 G

back to top

Blood Buddies: Pediatric Clinical Classical Hematology


Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 D
Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 D
Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 D
Friday, December 8, 2023
1:30 p.m. - 2:00 p.m.

Petco Park , Sections 122 and 124 D
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 D
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 D
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 D
Friday, December 8, 2023
2:40 p.m. - 3:10 p.m.

Petco Park , Sections 122 and 124 D

back to top

Blood Buddies: Pediatric Clinical Classical Hematology


Friday, December 8, 2023, 4:35 p.m. - 5:00 p.m.
Petco Park , Sections 122 and 124 D

back to top

65th ASH Annual Meeting Registration

San Diego Convention Center

Registration is now open for members, non-members, groups, exhibitors, and media!

View Registration Information